Ernesto Lamadrid
General Practice · Gainesville, FLNPI 1578777140
Payments from drug & device makers
Across 651 payments — averaging $196.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$75K
- Gilead$23K
- Merck$22K
- AbbVie$3K
- Johnson & Johnson$781
- Sanofi-aventis U.S. LLC$740
- plus $3K from 23 others
What the payments were for
- Consulting fees$17,21013%
- Speaking & faculty fees$81,66364%
- Travel & lodging$16,45013%
- Food & beverage$12,52610%
- Education$2370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 174 | $75,480 |
| Gilead | 106 | $22,643 |
| Merck | 79 | $22,253 |
| AbbVie(2 entities) | 18 | $2,724 |
| Johnson & Johnson(2 entities) | 63 | $781 |
| Sanofi-aventis U.S. LLC | 35 | $740 |
| AstraZeneca | 28 | $488 |
| Lilly USA, LLC | 30 | $430 |
| Novo Nordisk | 26 | $406 |
| Napo Pharmaceuticals Inc | 8 | $346 |
| Boehringer Ingelheim | 16 | $267 |
| Theratechnologies Inc. | 13 | $227 |
| Janssen Products, LP | 2 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $194 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $161 |
| Pfizer | 9 | $160 |
| Amgen(2 entities) | 7 | $117 |
| GSK | 6 | $98 |
| Janssen Scientific Affairs, LLC | 1 | $76 |
| Nestle Healthcare Nutrition Inc. | 4 | $63 |
| Smith+Nephew | 3 | $55 |
| EMD Serono, Inc. | 3 | $46 |
| Octapharma USA, Inc. | 1 | $30 |
| Abbott | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Kvk-tech, Inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,085 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $53,704 |
| Abilify MaintenaAripiprazole | 11 | $31,861 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,193 |
| Gabapentin | 11 | $116 |
| Lamotrigine | 11 | $54 |
| Duloxetine Hcl | 11 | $50 |
| Pantoprazole Sodium | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $22,643 | $53,70414 claims |
| GSKBreo Ellipta | $98 | $4,19311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Gainesville
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.